Sangamo Therapeutics (SGMOQ) Common Equity (2010 - 2025)

Sangamo Therapeutics has reported Common Equity for 16 years, with the latest figure at -$14.3 million in Q4 2025.

• On a quarterly basis, Common Equity fell 162.66% year-over-year to -$14.3 million in Q4 2025; TTM through Dec 2025 was -$14.3 million, a 162.66% decrease from a year earlier, with the FY2025 full-year figure at -$14.3 million, down 162.66% from the prior year.
• Common Equity was -$14.3 million for Q4 2025 at Sangamo Therapeutics, down from $6.2 million in the prior quarter.
• The five-year high for Common Equity was $960.0 million in Q2 2024, with the low at -$14.3 million in Q4 2025.
• Average Common Equity over 5 years is $262.1 million, with a median of $302.1 million recorded in 2022.
• The sharpest annual moves came in 2023 and 2025: Common Equity jumped 101.08% in 2023, then tumbled 162.66% in 2025.
• Over 5 years, Common Equity stood at $375.3 million in 2021, then retreated by 21.42% to $295.0 million in 2022, then slumped by 71.9% to $82.9 million in 2023, then sank by 72.53% to $22.8 million in 2024, then plunged by 162.66% to -$14.3 million in 2025.
• The last three Common Equity figures came in at -$14.3 million (Q4 2025), $6.2 million (Q3 2025), and $19.6 million (Q2 2025), per Business Quant data.